Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading experts
Retrieved on:
星期四, 四月 25, 2024
Genetics, CMO, Doctor of Philosophy, Boston, Development, Novartis, Pfizer, Operating partner, Functional genomics, CSO, Genome, Associate, Drug discovery, SAB, AbbVie, Baxalta, EVP, GSK plc, Bristol Myers Squibb, GSK, Baylor College of Medicine, University, Harvard Medical School, Therapy, Biotechnology, Inflammation, Hospital, NIH, Michigan State University, Respiratory Medicine, Imperial College London, IPO, Rockefeller University, Spatial, MPH, Genomics, Atlas Venture, Merck Serono, Genentech, University of Birmingham, Senior, Society, Acquisition, Discovery, Sanofi, Baylor University
New Non-Executive Director of the Board, John Davis MD, MPH, MS, brings extensive and varied experience as a physician-scientist, drug developer and biotechnology executive.
Key Points:
- New Non-Executive Director of the Board, John Davis MD, MPH, MS, brings extensive and varied experience as a physician-scientist, drug developer and biotechnology executive.
- The SAB is chaired by Prof. Jim Hughes, Scientific Founder and Non-Executive Director of Nucleome Therapeutics.
- Dr Russell Greig, Non-Executive Chair of the Nucleome’s Board, said: “We are delighted to have appointed such esteemed experts to the Nucleome team.
- Steve’s multifaceted background, spanning academia, industry and leadership roles, positions him as a key contributor to Nucleome’s Scientific Advisory Board.